Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in Cancer Letters
- Vol. 479, 89-99
- https://doi.org/10.1016/j.canlet.2020.03.013
Abstract
No abstract availableFunding Information
- JSPS KAKENHI (JP19K18617, JP16H06276)
This publication has 45 references indexed in Scilit:
- Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacyOncoImmunology, 2015
- Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 EfficacyScience Translational Medicine, 2014
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancerProceedings of the National Academy of Sciences of the United States of America, 2013
- Second-line systemic therapy for metastatic urothelial carcinoma of the bladderFuture Oncology, 2013
- Autocrine CCL2 promotes cell migration and invasion via PKC activation and tyrosine phosphorylation of paxillin in bladder cancer cellsCytokine, 2012
- A CXCL1 Paracrine Network Links Cancer Chemoresistance and MetastasisCell, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Circulating and tumor‐infiltrating myeloid cell subsets in patients with bladder cancerInternational Journal of Cancer, 2011
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009